文献速递真菌感染艾滋病与性传播感染医院感染防控

1999-2018年美国危险因素与侵袭性真菌病死亡率趋势

Mortality Trends in Risk Conditions and Invasive Mycotic Disease in the United States, 1999-2018.
PubMed 文献 · Clin Infect Dis · 2022-01-01

该分析基于美国国家生命统计系统1999至2018年数据,估计危险因素及相关真菌病归因死亡。结果显示真菌病死亡1999至2010年大幅下降主要因HIV控制,但非HIV人群真菌诊断死亡增加,糖尿病、癌症、免疫抑制或脓毒症患者显著上升,近年真菌感染总数增加。

要点

  • 2018年死亡时伴真菌相关危险因素诊断达1 047 422例。
  • 非HIV人群真菌诊断死亡增加,糖尿病、癌症、免疫抑制、脓毒症显著上升。
  • 近年真菌感染总数增加,提示新免疫抑制人群真菌死亡控制不佳。

核心结论

  • 真菌病高危人群构成正在变化,HIV相关发病持续下降,但癌症、脓毒症、免疫抑制和流感患者真菌诊断增加。
  • 近年真菌感染总数总体增加,表明新免疫抑制人群中真菌病死亡控制失败。

研究设计与样本

  • 分析美国国家生命统计系统1999至2018年数据,估计危险因素及相关真菌病归因死亡。

主要发现

  • 2018年死亡时伴真菌相关危险因素诊断共1 047 422例。
  • 真菌病死亡1999至2010年大幅下降,主要归因于HIV感染控制。
  • 非HIV队列中伴真菌诊断死亡增加,糖尿病、癌症、免疫抑制疾病或脓毒症患者显著增加。

临床怎么用

  • 临床应关注非HIV免疫抑制患者(如癌症、脓毒症、糖尿病、免疫抑制疾病)的真菌病风险。
  • 需改进真菌病预防与管理以控制高危人群的发病与死亡。

局限性

  • 侵袭性真菌感染在美国长期诊断不足,缺乏协调监测使真实疾病负担难以确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Invasive fungal infections in the United States are chronically underdiagnosed and a lack of coordinated surveillance makes the true burden of disease difficult to determine. The purpose of this analysis was to capture mortality-associated burden of risk conditions and fungal infections. METHODS: We analyzed data from the National Vital Statistics System from 1999 through 2018 to estimate the mortality attributed to risk conditions and related fungal disease. RESULTS: The number of risk conditions associated with fungal disease is steadily rising in the United States, with 1 047 422 diagnoses at time of death in 2018. While fungal disease decreased substantially from 1999 to 2010, primarily due to the control of human immunodeficiency virus (HIV) infection, the number of deaths with fungal diagnosis has increased in the non-HIV cohort, with significant increases in patients with diabetes, cancer, immunosuppressive disorders, or sepsis. CONCLUSIONS: The landscape of individuals at risk for serious fungal diseases is changing, with a continued decline in HIV-associated incidence but increased diagnoses in patients with cancer, sepsis, immunosuppressive disorders, and influenza. Additionally, there is an overall increase in the number of fungal infections in recent years, indicating a failure to control fungal disease mortality in these new immunocompromised cohorts. Improvement in the prevention and management of fungal diseases is needed to control morbidity and mortality in the rising number of immunocompromised and at-risk patients in the United States.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Rayens E, Norris KA, Cordero JF, et al. Mortality Trends in Risk Conditions and Invasive Mycotic Disease in the United States, 1999-2018. Clin Infect Dis. 2022. PMID: 33876235. doi:10.1093/cid/ciab336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。